Roivant Sciences Ltd. $ROIV Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 38,804,928 shares of the company’s stock after selling 521,408 shares during the quarter. Vanguard Group Inc. owned 0.06% of Roivant Sciences worth $587,119,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Bessemer Group Inc. raised its holdings in Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. CWM LLC raised its stake in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after acquiring an additional 920 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in Roivant Sciences by 1.2% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 86,652 shares of the company’s stock worth $1,311,000 after acquiring an additional 1,019 shares during the period. Jones Financial Companies Lllp increased its holdings in Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after purchasing an additional 1,148 shares during the last quarter. Finally, M&T Bank Corp raised its stake in shares of Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after purchasing an additional 1,181 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Several brokerages have raised price targets and maintained buy ratings (Goldman Sachs, HC Wainwright, Citi among them), and the street consensus is a “Moderate Buy” — a catalyst supporting demand for the shares. Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Institutional ownership is substantial (~65%) and recent filings show new and increased positions by several funds — this can sustain liquidity and limit extreme volatility but also means moves can be driven by fund flows. ROIV Stock Profile and Institutional Trading (MarketBeat)
• Negative Sentiment: Frank Torti sold roughly 3.0M shares across Feb. 19–23 for about $82M in aggregate (multiple Form 4 filings), trimming his stake — a sizable insider disposition that can create downward pressure or signal owner liquidity needs. Frank Torti Sells 587,390 Shares of Roivant Sciences (NASDAQ:ROIV) Stock Un initié de Roivant Sciences cède des actions pour une valeur de 82 039 460 $, selon un récent dépôt à la SEC

Insider Activity

In other Roivant Sciences news, CEO Matthew Gline sold 1,740,000 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $21.68, for a total transaction of $37,723,200.00. Following the sale, the chief executive officer directly owned 17,290,820 shares in the company, valued at approximately $374,864,977.60. The trade was a 9.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mayukh Sukhatme sold 1,018,995 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the transaction, the insider owned 20,267,429 shares in the company, valued at $440,005,883.59. This represents a 4.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,318,014 shares of company stock worth $315,727,023 in the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ROIV. HC Wainwright increased their target price on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. The Goldman Sachs Group upped their target price on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. Weiss Ratings cut Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Jefferies Financial Group restated a “buy” rating and set a $30.00 price objective on shares of Roivant Sciences in a research report on Monday, February 9th. Finally, Guggenheim upped their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $28.69.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $28.26 on Wednesday. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $28.29. The firm has a market capitalization of $20.23 billion, a PE ratio of -24.15 and a beta of 1.22. The stock has a fifty day moving average of $23.54 and a two-hundred day moving average of $19.19.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.